Marc Russo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marc Russo has a total of 398 co-authors. Here are the top co-authors by number of shared publications:
- Danielle M. Santarelli
Genesis Research Services, Broadmeadow, NSW, Australia
18 shared publications - Timothy Ray Deer
Spine and Nerve Center of the Virginias, West Virginia University, Thomas Health Campus, Charleston, WV 25309, USA
11 shared publications Danielle M. Santarelli
Genesis Research Services, Broadmeadow, NSW, Australia
9 shared publicationsPeter Georgius
Sunshine Coast Clinical Research , Noosa Heads, QLD
9 shared publicationsPaul Verrills
Metropain, Melbourne, VIC, Australia
8 shared publicationsRichard Sullivan
Precision Brain Spine & Pain Centre, Kew, Australia
8 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Elsevier in The Journal of Pain
- Vol. 50
Ultra-high field functional magnetic resonance imaging reveals subregional hypothalamic and brainstem activation patterns in response to noxious heat stimuli in complex regional pain syndrome
- 17 September 2026
- Published by Elsevier in The Journal of Pain
- Vol. 50
Open AccessUltra-high field functional magnetic resonance imaging reveals subregional hypothalamic and brainstem activation patterns in response to noxious heat stimuli in complex regional pain syndrome
- Open Access
- 28 July 2026
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (5) , 1673-1684
In-Clinic and At-Home Patient Experiences with Closed-Loop Spinal Cord Stimulation: 12-Month Outcomes from the Closed-Loop Australia Randomized Crossover Trial
- 28 July 2026
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (5) , 1673-1684
Open AccessIn-Clinic and At-Home Patient Experiences with Closed-Loop Spinal Cord Stimulation: 12-Month Outcomes from the Closed-Loop Australia Randomized Crossover Trial
- 21 January 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (6) , 715-716
Author response
- 21 January 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (6) , 715-716
Author response
- 25 October 2025
- Published by Elsevier in BJA Education
- Vol. 25 (12) , 511-519
Advances in spinal cord stimulation
- 25 October 2025
- Published by Elsevier in BJA Education
- Vol. 25 (12) , 511-519
Advances in spinal cord stimulation
- Open Access
- 17 June 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-2
Letter to the editor concerning “A meta-analysis and systematic review of the clinical efficacy and safety of platelet-rich plasma combined with hyaluronic acid (PRP + HA) versus PRP monotherapy for knee osteoarthritis (KOA)”
Platelet-rich plasma (PRP) is commonly used alone or in combination with hyaluronic acid (HA) in the treatment of knee osteoarthritis. A recently published meta-analysis and systematic review compared outcomes between PRP + HA combination therapy and PRP monotherapy. This letter addresses a critical concern with the study and seeks clarification from the authors.
- 17 June 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-2
Open AccessLetter to the editor concerning “A meta-analysis and systematic review of the clinical efficacy and safety of platelet-rich plasma combined with hyaluronic acid (PRP + HA) versus PRP monotherapy for knee osteoarthritis (KOA)”
Platelet-rich plasma (PRP) is commonly used alone or in combination with hyaluronic acid (HA) in the treatment of knee osteoarthritis. A recently published meta-analysis and systematic review compared outcomes between PRP + HA combination therapy and PRP monotherapy. This letter addresses a critical concern with the study and seeks clarification from the authors.
- 20 May 2025
- Published by Wiley in Pain Practice
- Vol. 25 (5) , e70045
Demystifying Spinal Cord Stimulation as Not More Than a Placebo: An Evidence‐Based Perspective
- 20 May 2025
- Published by Wiley in Pain Practice
- Vol. 25 (5) , e70045
Demystifying Spinal Cord Stimulation as Not More Than a Placebo: An Evidence‐Based Perspective
- Open Access
- 16 May 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (11) , 773-782
Early outcomes with a flexible ECAP based closed loop using multiplexed spinal cord stimulation waveforms—single-arm study with in-clinic randomized crossover testing
Background: Spinal cord stimulation (SCS) systems that deliver fixed amplitudes expose target tissue to varying electrical fields due to the changing lead-to-cord distance accompanying postural shifts and other body movements. Inconsistent stimulation results in periods of overstimulation or under-stimulation perceived by patients as discomfort or potentially inadequate pain relief. CL-SCS may be applied to provide a comfortable level of perception down to imperceptible stimulation, commonly preferred in higher frequency and multiplexed programming. Here we report outcomes from a study evaluating a closed-loop (CL) SCS system that uses spinal evoked compound action potentials to adjust stimulation. Methods: This ongoing study combines the evaluation of pain-related outcomes (for ≤24 months) with in-clinic randomized, crossover testing of CL performance. Results: Sixty subjects have been implanted with the CL-SCS system, and 54 subjects have completed the 3-month visit. Sixty percent preferred below-perception waveforms for therapy during at-home use. The study successfully met its primary endpoint with 89.3% of subjects in the Primary Analysis Set (n = 28) reporting reduction in overstimulation with CL-SCS relative to OL-SCS at 1 month (P < .001; binomial exact test); at 3 months, 86% of subjects with low-back/leg pain (n = 51); and all 3 with upper limb pain reported ≥50% reduction in pain, relative to baseline. Conclusions: The data presented here support the performance of a flexible CL-SCS system that can deliver a variety of waveforms, with amplitude programmed to patient comfort and automatically adjusted up to 50 times per second, to improve the consistency of therapy experience. Registration: This study is registered on ClinicalTrials.gov number NCT05177354 https://clinicaltrials.gov/search? term=NCT05177354
- 16 May 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (11) , 773-782
Open AccessEarly outcomes with a flexible ECAP based closed loop using multiplexed spinal cord stimulation waveforms—single-arm study with in-clinic randomized crossover testing
Background: Spinal cord stimulation (SCS) systems that deliver fixed amplitudes expose target tissue to varying electrical fields due to the changing lead-to-cord distance accompanying postural shifts and other body movements. Inconsistent stimulation results in periods of overstimulation or under-stimulation perceived by patients as discomfort or potentially inadequate pain relief. CL-SCS may be applied to provide a comfortable level of perception down to imperceptible stimulation, commonly preferred in higher frequency and multiplexed programming. Here we report outcomes from a study evaluating a closed-loop (CL) SCS system that uses spinal evoked compound action potentials to adjust stimulation. Methods: This ongoing study combines the evaluation of pain-related outcomes (for ≤24 months) with in-clinic randomized, crossover testing of CL performance. Results: Sixty subjects have been implanted with the CL-SCS system, and 54 subjects have completed the 3-month visit. Sixty percent preferred below-perception waveforms for therapy during at-home use. The study successfully met its primary endpoint with 89.3% of subjects in the Primary Analysis Set (n = 28) reporting reduction in overstimulation with CL-SCS relative to OL-SCS at 1 month (P < .001; binomial exact test); at 3 months, 86% of subjects with low-back/leg pain (n = 51); and all 3 with upper limb pain reported ≥50% reduction in pain, relative to baseline. Conclusions: The data presented here support the performance of a flexible CL-SCS system that can deliver a variety of waveforms, with amplitude programmed to patient comfort and automatically adjusted up to 50 times per second, to improve the consistency of therapy experience. Registration: This study is registered on ClinicalTrials.gov number NCT05177354 https://clinicaltrials.gov/search? term=NCT05177354
- 3 February 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (6) , 337-347
Systematic review and meta-analysis of conventional medical management in a patient population with refractory chronic pain suitable to receive a spinal cord stimulation system
Aim: The aim of this review was to systematically identify all evidence that used conventional medical management (CMM) as a comparator in randomized controlled trials (RCTs) of spinal cord stimulation (SCS) therapy, and to conduct a meta-analysis to investigate if continued CMM provides statistical or clinically meaningful pain relief and whether CMM effects have improved over the last few decades. Methods: Databases were searched from inception to June 2024 for RCTs that compared SCS to CMM. The primary outcome of the review was absolute change in pain intensity from baseline to the last available follow-up in the CMM group, measured using a visual analogue scale or numerical rating scale. The measure of treatment effect for absolute change and percentage change in pain intensity from baseline was mean difference (MD) and 95% confidence interval (CI). Risk of bias (RoB) was assessed by using the revised Cochrane RoB tool. The protocol for this review is registered on PROSPERO (CRD42023449215). Results: Meta-analysis of absolute change in pain intensity from baseline to last follow-up shows that CMM is not associated with any significant reductions in pain intensity (MD −0.11; 95% CI: −0.32 to 0.11; moderate certainty). Similar results were observed for percent change in pain intensity from baseline to last follow-up (MD −3.22%; 95% CI: −12.59% to 6.14%; moderate certainty). No significant differences were observed when considering decade of publication of the RCT for absolute (P = .065; moderate certainty) or percent change in pain intensity (P = 0.524; moderate certainty). Meta-analysis for 6-month follow-up and sensitivity analysis shows similar numerical results. Conclusion: Our findings show that continued CMM for a population eligible for SCS does not provide meaningful pain relief and has not considerably changed over the last few decades. The use of CMM as the control to evaluate relative SCS treatment effects should be reassessed.
- 3 February 2025
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 26 (6) , 337-347
Systematic review and meta-analysis of conventional medical management in a patient population with refractory chronic pain suitable to receive a spinal cord stimulation system
Aim: The aim of this review was to systematically identify all evidence that used conventional medical management (CMM) as a comparator in randomized controlled trials (RCTs) of spinal cord stimulation (SCS) therapy, and to conduct a meta-analysis to investigate if continued CMM provides statistical or clinically meaningful pain relief and whether CMM effects have improved over the last few decades. Methods: Databases were searched from inception to June 2024 for RCTs that compared SCS to CMM. The primary outcome of the review was absolute change in pain intensity from baseline to the last available follow-up in the CMM group, measured using a visual analogue scale or numerical rating scale. The measure of treatment effect for absolute change and percentage change in pain intensity from baseline was mean difference (MD) and 95% confidence interval (CI). Risk of bias (RoB) was assessed by using the revised Cochrane RoB tool. The protocol for this review is registered on PROSPERO (CRD42023449215). Results: Meta-analysis of absolute change in pain intensity from baseline to last follow-up shows that CMM is not associated with any significant reductions in pain intensity (MD −0.11; 95% CI: −0.32 to 0.11; moderate certainty). Similar results were observed for percent change in pain intensity from baseline to last follow-up (MD −3.22%; 95% CI: −12.59% to 6.14%; moderate certainty). No significant differences were observed when considering decade of publication of the RCT for absolute (P = .065; moderate certainty) or percent change in pain intensity (P = 0.524; moderate certainty). Meta-analysis for 6-month follow-up and sensitivity analysis shows similar numerical results. Conclusion: Our findings show that continued CMM for a population eligible for SCS does not provide meaningful pain relief and has not considerably changed over the last few decades. The use of CMM as the control to evaluate relative SCS treatment effects should be reassessed.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 531-551
The American Society of Pain and Neuroscience (ASPN) Guidelines and Consensus on the Definition, Current Evidence, Clinical Use and Future Applications for Physiologic Closed-Loop Controlled Neuromodulation in Chronic Pain: A NEURON Group Project
Introduction: Neuromodulation has been a staple of treatment for moderate-to-severe chronic refractory pain since the introduction of the first spinal cord stimulator by Norman Shealy in 1967. Appreciating the dynamic nature of electrical modulation of the nervous system from the epidural space, the goal has been consistent, reliable, and therapeutic neural activation of the spinal cord. This has proven to be extremely difficult. Recently, the Food and Drug Administration (FDA) released a guidance on physiologic closed loop controlled (PCLC) devices, highlighting the potential for these therapies to deliver accurate, consistent, real-time therapy, enhancing medical care and reducing variability. Because of the growing neuromodulation market focus on PCLC strategies, the American Society of Pain and Neuroscience (ASPN) sought to develop guidance on safety and efficacy, along with a taxonomy surrounding PCLC systems (PCLCSs) and to develop an evidence-based best practice review. Methods: A librarian-assisted literature search was performed to identify manuscripts relevant to the topic of PCLC stimulation for management of chronic pain. Initial literature search was performed utilizing MEDLINE, EMBASE, Cochrane database, BioMed Central, and Web of Science. Included manuscripts encompassed meta-analyses, systematic reviews, randomized controlled trials (RCTs), prospective or retrospective studies with follow-up to 12 months, limited to the English language. MESH terms utilized included “closed-loop”, “physiologic closed loop controlled”, “spinal cord stimulation”, “closed loop feedback”, “feedback controlled”, “neuromodulation”, “pain”, “persistent pain”, “neuropathic pain”, and “chronic pain”. The modified USPSTF evidence and recommendation grading strategy previously utilized was again employed. Results: Four studies were identified for review, 2 prospective, one retrospective, and one randomized controlled study with at least 12-month follow-up. Conclusion: PCLC neuromodulation is an innovation that requires a responsible introduction. As commercial access grows, there is a responsibility that requires consistency with definition, evidence generation, focused on safety and efficacy.
- 1 February 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 531-551
Open AccessThe American Society of Pain and Neuroscience (ASPN) Guidelines and Consensus on the Definition, Current Evidence, Clinical Use and Future Applications for Physiologic Closed-Loop Controlled Neuromodulation in Chronic Pain: A NEURON Group Project
Introduction: Neuromodulation has been a staple of treatment for moderate-to-severe chronic refractory pain since the introduction of the first spinal cord stimulator by Norman Shealy in 1967. Appreciating the dynamic nature of electrical modulation of the nervous system from the epidural space, the goal has been consistent, reliable, and therapeutic neural activation of the spinal cord. This has proven to be extremely difficult. Recently, the Food and Drug Administration (FDA) released a guidance on physiologic closed loop controlled (PCLC) devices, highlighting the potential for these therapies to deliver accurate, consistent, real-time therapy, enhancing medical care and reducing variability. Because of the growing neuromodulation market focus on PCLC strategies, the American Society of Pain and Neuroscience (ASPN) sought to develop guidance on safety and efficacy, along with a taxonomy surrounding PCLC systems (PCLCSs) and to develop an evidence-based best practice review. Methods: A librarian-assisted literature search was performed to identify manuscripts relevant to the topic of PCLC stimulation for management of chronic pain. Initial literature search was performed utilizing MEDLINE, EMBASE, Cochrane database, BioMed Central, and Web of Science. Included manuscripts encompassed meta-analyses, systematic reviews, randomized controlled trials (RCTs), prospective or retrospective studies with follow-up to 12 months, limited to the English language. MESH terms utilized included “closed-loop”, “physiologic closed loop controlled”, “spinal cord stimulation”, “closed loop feedback”, “feedback controlled”, “neuromodulation”, “pain”, “persistent pain”, “neuropathic pain”, and “chronic pain”. The modified USPSTF evidence and recommendation grading strategy previously utilized was again employed. Results: Four studies were identified for review, 2 prospective, one retrospective, and one randomized controlled study with at least 12-month follow-up. Conclusion: PCLC neuromodulation is an innovation that requires a responsible introduction. As commercial access grows, there is a responsibility that requires consistency with definition, evidence generation, focused on safety and efficacy.